Differentiated Profile of AMB-702, a Next-Generation Oral Small Molecule GLP-1 Receptor Agonist Development Candidate

• The need for differentiated GLP-1 agonists, including small molecules with lower effective human dosing, a flatter peak-to-trough and a path to combinability with other agents
• Preclinical data supporting Ambrosia’s GLP-1 development candidate, including comparator data

Speakers:

Erik Hicken

Head of Chemistry

Ambrosia Biosciences